Pfizer (PFE) says Danuglipron trial patient developed potential drug-induced liver injury; Pfizer ends development of Danuglipron GLP-1 pill for weight loss
Reaction details (11:46)
- PFE -3% in pre-market trade.
- LLY +2.3% in pre-market trade.
- VKTX +10%.
- NVO +3.5%.
Analysis details (11:46)
- Of note for Eli Lilly (LLY) and Novo Nordisk (NOVOB DC)
14 Apr 2025 - 11:45- EquitiesImportant- Source: Newswires
Subscribe Now to Newsquawk
Click here for a 1 week free trial
Newsquawk provides audio news and commentary for over 15,000professional traders and brokers worldwide. Services include:
- Real-time audio coverage from 0630 to 2200 London time plus Asia-Pac 2200 to 1000 London time
- Teams of analysts covering equities, fixed income, FX, energy, and metals markets
- Real-time scrolling news service with instant analysis
- Daily and weekly pre-market research and calendars
- Video updates covering near-term key risk events & primary trading themes
- One-to-one chat with our expert analysts